BACKGROUND: Osteoporotic fractures have a serious economic impact on society and on the quality of life of patients. Differences in opinions on the desirability of preventive treatment initiation may hamper the process and outcome of shared decision making between physician and patient. OBJECTIVE: To evaluate and compare preferences of GPs and patients for preventive osteoporosis drug treatment. METHODS: Discrete-choice experiment (DCE) involving 34 general practices in the area of Rotterdam, the Netherlands. Participants included 40 GPs and 120 women aged > or = 60 years who participated in a study on osteoporosis case finding. We included any woman aged >60 years, with an over-representation of women with a high fracture risk (n = 60). OUTCOMES: (i) The relative weights that GPs and patients place on five treatment attributes of preventive osteoporosis drug treatment: effectiveness, nausea as an adverse effect, total treatment duration, route of drug administration and out-of-pocket costs; and (ii) the determinants of any differences in preferences between GPs and patients. RESULTS: The response rate was 40/59 (68%) for GPs and 120/181 (66%) for patients. All treatment attributes proved to be important for preferences of GPs and patients. GPs had a significantly less favourable attitude towards preventive osteoporosis drug treatment than patients; they placed significantly higher values on effectiveness of preventive drug treatment and short total preventive treatment duration than patients. CONCLUSIONS: GPs and patients showed different preferences towards preventive osteoporosis drug treatment. Addressing each of these differences may have a positive effect on the process and outcomes of shared decision making regarding preventive treatment initiation.
BACKGROUND:Osteoporotic fractures have a serious economic impact on society and on the quality of life of patients. Differences in opinions on the desirability of preventive treatment initiation may hamper the process and outcome of shared decision making between physician and patient. OBJECTIVE: To evaluate and compare preferences of GPs and patients for preventive osteoporosis drug treatment. METHODS: Discrete-choice experiment (DCE) involving 34 general practices in the area of Rotterdam, the Netherlands. Participants included 40 GPs and 120 women aged > or = 60 years who participated in a study on osteoporosis case finding. We included any woman aged >60 years, with an over-representation of women with a high fracture risk (n = 60). OUTCOMES: (i) The relative weights that GPs and patients place on five treatment attributes of preventive osteoporosis drug treatment: effectiveness, nausea as an adverse effect, total treatment duration, route of drug administration and out-of-pocket costs; and (ii) the determinants of any differences in preferences between GPs and patients. RESULTS: The response rate was 40/59 (68%) for GPs and 120/181 (66%) for patients. All treatment attributes proved to be important for preferences of GPs and patients. GPs had a significantly less favourable attitude towards preventive osteoporosis drug treatment than patients; they placed significantly higher values on effectiveness of preventive drug treatment and short total preventive treatment duration than patients. CONCLUSIONS: GPs and patients showed different preferences towards preventive osteoporosis drug treatment. Addressing each of these differences may have a positive effect on the process and outcomes of shared decision making regarding preventive treatment initiation.
Authors: H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych Journal: Osteoporos Int Date: 1999 Impact factor: 4.507
Authors: M Ryan; D A Scott; C Reeves; A Bate; E R van Teijlingen; E M Russell; M Napper; C M Robb Journal: Health Technol Assess Date: 2001 Impact factor: 4.014
Authors: S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller Journal: JAMA Date: 1999-10-13 Impact factor: 56.272
Authors: E W de Bekker-Grob; M L Essink-Bot; W J Meerding; H A P Pols; B W Koes; E W Steyerberg Journal: Osteoporos Int Date: 2008-01-08 Impact factor: 4.507
Authors: J Darbà; G Restovic; L Kaskens; M A Balbona; A Carbonell; P Cavero; M Jordana; C Prieto; A Molina; I Padró Journal: Osteoporos Int Date: 2010-09-14 Impact factor: 4.507
Authors: S Silverman; A Calderon; K Kaw; T B Childers; B A Stafford; W Brynildsen; A Focil; M Koenig; D T Gold Journal: Osteoporos Int Date: 2012-12-18 Impact factor: 4.507